Source comparison
Comparison: PT-141 Interaction Profile Across Common Substances
Caffeine (200–300mg) Adenosine receptor antagonist → vasoconstriction Pharmacological opposition (efficacy risk, not safety risk) Avoid 2 hours before and after PT-141 No documented adverse events; mechanism suggests efficacy reduction Timing matters more than
This comparison does not assign a generated winner or score.
- Caffeine (200–300mg)
- Adenosine receptor antagonist → vasoconstriction
- Pharmacological opposition (efficacy risk, not safety risk)
- Avoid 2 hours before and after PT-141
- No documented adverse events; mechanism suggests efficacy reduction
- Timing matters more than abstinence. Space consumption by 4+ hours
- Alcohol (2+ drinks)
- CNS depressant + vasodilator
- Additive hypotensive effect
- Avoid concurrent use on administration day
- Case reports of severe hypotension when combined
- Hard contraindication. Vasodilation overlap creates blood pressure risk
- Sildenafil (PDE5 inhibitors)
- cGMP phosphodiesterase inhibitor → vasodilation
- Synergistic vasodilation (hypotension risk)
- Contraindicated. Do not combine
- FDA black box warning for melanocortin + PDE5 combination
- Dangerous. Both lower blood pressure through different pathways
- L-citrulline (6–8g)
- Nitric oxide precursor → vasodilation
- Potentially synergistic (may enhance PT-141 effect)
- Safe to combine; no spacing required
- No interaction studies; shared NO pathway is mechanistically compatible
- Likely safe and potentially beneficial. Monitor blood pressure
- Nicotine (vaping, smoking)
- Sympathetic stimulant → vasoconstriction
- Pharmacological opposition (similar to caffeine)
- Avoid 1–2 hours around PT-141 peak
- No specific PT-141 data; general vasoconstrictor interaction principles apply
- Reduces efficacy through same adenosine/catecholamine pathways as caffeine
- Beta-blockers (atenolol, metoprolol)
- Beta-adrenergic antagonist → reduced cardiac output
- Blunts PT-141's blood pressure elevation
- Consult prescribing physician before PT-141 use
- Theoretical interaction; no clinical case reports
- Safe from interaction standpoint but may mask PT-141's cardiovascular response
- The bottom line: PT-141 with coffee safety is not about toxicity. It's about efficacy loss. Caffeine doesn't create dangerous interactions the way alcohol or PDE5 inhibitors do, but it does reduce the magnitude of PT-141's intended vascular effect through opposing receptor mechanisms. Strategic timing eliminates this interference entirely.